DLG4 and glaucoma: Conversely, PSD95 levels were enhanced in NS−/− glaucoma (p < 0.02) and significantly reduced in response to M363R-NS treatment (p < 0.04; p < 0.02) compared with WT NS (Figures S49A and S49C).